Clinical Trials Logo

Clinical Trial Summary

As a prospective, multi-center study, GUIDER will recruit 400 liver nodules participants from different provinces and regions across China. Except for cfDNA signatures, serum biomarkers, histopathological biopsy and enhanced MRI will also be performed. The sensitivity and specificity of the cfDNA signature based-model in liver nodules diagnosing will be evaluated.


Clinical Trial Description

Patients with liver nodules will be recruited for 1 year. Peripheral blood samples of all participants will be collected after being informed about the study and potential risks. CfDNA extraction, library construction, and whole genome sequencing will be performed. A machine learning method will be implemented for cfDNA signatures-based model construction at the end of the study. Sensitivity and specificity will be used to evaluate the performance of cfDNA signatures-based model in liver nodules diagnosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05393102
Study type Observational
Source The Second Affiliated Hospital of Chongqing Medical University
Contact Hong Ren, MD
Phone 13983888786
Email renhong0531@vip.sina.com.cn
Status Not yet recruiting
Phase
Start date May 2022
Completion date October 2023

See also
  Status Clinical Trial Phase
Completed NCT00781924 - Interventional Sonography Guided by Image Fusion N/A
Recruiting NCT03871140 - Utility of Ultrasound Imaging for Diagnosis of Focal Liver Lesions: A Radiomics Analysis
Recruiting NCT04682886 - Radiomics Analysis of Focal Liver Lesions Based on Contrast-Enhanced Ultrasound Imaging
Completed NCT00243633 - Characterization of Focal Liver Lesions by Real-Time Contrast-Enhanced Ultrasound Imaging (CEUS) N/A